Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: Implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 39-47

  Brooks, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesia; Entacapone; Levodopa; Stalevo; Wearing off

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; MADOPAR CR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; INSOMNIA; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; SIDE EFFECT; UNIFIED PARKINSON DISEASE RATING SCALE; URINE COLOR; VOMITING;

EID: 41549097751     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1660     Document Type: Article

References (37)

1. Brooks DJ, Sagar H. 2003. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry, 74:1071-9.
2. Chapuis S, et al. 2005. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord, 20:224-30.
3. Chaudhuri KR, et al. 2006. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol, 5:235-45.
4. de la Fuente-Fernandez R, et al. 2001. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol, 49:298-303.
5. Dorsey ER, et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68:384-6.
6. Dupont E, et al. 1996. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand, 93:14-20.
7. Fahn S. 2005. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol, 252:iv37-42.
8. Fung V. 2006. A randomized, double - blind study to compare the effect on quality of life of levodopa/carbidopa/entacapone(Stalevo) with levodopa/carbidopain patients with Parkinson's disease with no or minimal, non-disabling motor fluctuations. Movement Disorder Society of Australia Clinical Research and Trials Group (MDSCRTG) and QUEST-AP Study Group. Mov Disord, 21:S446 Abstract #37.
9. Grosset KA, et al. 2005. Suboptimal medication adherence in Parkinson's disease. Mov Disord, 20:1502-7.
10. Haapaniemi H, et al. 2001. Tolerability and safety of entacapone in the treatment of Parkinson's disease. Parkinsonism Relat Disord, 7:S57.
11. Holloway RG, et al. 2004. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-53.
12. Katzenschlager R, et al. 2003. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev, CD003735.
13. Koller WC, et al. 1999. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology, 53:1012-9.
14. Larsen JP, et al. 2003. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol, 10: 137-46.
15. Litvan I, et al. 2003. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord, 18:467-86.
16. Maier Hoehn MM. 1983. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl, 19:253-64.
17. Marsden CD, Parkes JD, 1977. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet, 1:345-9.
18. Muller T, et al. 2006. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma. levels. Mov Disord, 21:33 2-6.
19. Myllyla V, et al. 2001. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol, 8:53-60.
20. Nissinen H, Kuoppamaki M, Leinonen M. 2006. Early initiation of entacapone leads to superior 5-year efficacy compared to delayed initiation in Parkinson's disease patients receiving traditional levodopa/DDCI therapy. Mov Disord, 21:S593.
21. Nutt JG, Fellman JH. 1984. Pharmacokinetics of levodopa. Clinical Neuropharmacology, 7:35-49.
22. Nyholm D, et al. 2003. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol, 26:156-63.
23. Oertel WH, et al. 2006. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord, 21:343-53.
24. Olanow CW, et al. 2006. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol, 5:677-87.
25. Parkinsons Study Group. 1997. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol, 42:747-55.
26. Poewe WH, et al. 2002. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand, 105:245-55.
27. PSG. 1997. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol, 42:747-55.
28. Rascol O, et al. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med, 342:1484-91.
29. Rascol O, et al. 2006. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord, 21:1844-50.
30. Rinne UK, et al. 1998. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology, 51:1309-14.
31. Sawle GV, et al. 1994. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology, 44:1292-7.
32. Schapira AH, Obeso J. 2006. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol, 59:559-62.
33. Silver DE. 2004. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother, 4:589-99.
34. Stalevo. 2007. US prescribing information [online]. Accessed March 2007. URL: http://www.pharma.us.novartis.com/product/pi/pdf/stalevo.pdf
35. Stocchi F. 2005. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol, 252:IV43-8.
36. Stocchi F. 2006. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother, 7:1399-407.
37. Wheatley K, et al. 2002. Evaluating drug treatments for Parkinson's disease: how good are the trials?. BMJ, 324: 1509-11.